TITLE

Should We Use Colchicine for Acute Gout, and If So, How Much?

AUTHOR(S)
Scherger, Joseph E.
PUB. DATE
July 2010
SOURCE
Internal Medicine Alert;7/29/2010, Vol. 32 Issue 14, p105
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses the use of Colchicum Automnale to cure acute gout.
ACCESSION #
53269503

 

Related Articles

  • Gout. Bayliss, R.I.S. // British Medical Journal;6/23/1979, Vol. 1 Issue 6179, p1695 

    Examines the treatment for gout arthritis. Management of pain during acute attacks of gout; Prevention of further pain attacks; Efficacy of colchicine as treatment.

  • The Management of Gout. Emmerson, Bryan T. // New England Journal of Medicine;2/15/96, Vol. 334 Issue 7, p445 

    Focuses on the drug treatment that is available for patients with gout. Description of gout; Established criteria for the diagnosis of gout; The benefit of colchicine in treatment; Nonsteroidal antiinflammatory drugs; Corticosteroids; Prophlaxis against acute gout; Causes of sustained...

  • Homeopathic Treatment of Acute Gout. Cara, Raakhi; Tikly, M.; Solomon, E. M.; Deroukakis, M. // American Journal of Homeopathic Medicine;Spring2007, Vol. 100 Issue 1, p40 

    The treatment of acute gout with the homeopathic similimum was investigated to determine its efficacy. The study focused on the homeopathic Law of Similars where a single most similar remedy was chosen according to the unique characteristic symptoms displayed by each participant suffering with...

  • Febuxostat: A Viewpoint by H. Ralph Schumacher Jr and Lan X. Chen. Schumacher, Jr, H. Ralph; Chen, Lan X. // Drugs;2008, Vol. 68 Issue 13, p1877 

    The article presents the author's views on febuxostat, a urate-lowering drug that could be used in the treatment of gout. The author believes that treatment should focus on reducing inflammation in acute attacks of gout and on assessing the metabolic defect that permits the accumulation of...

  • Febuxostat: A Viewpoint by Naomi Schlesinger. Schlesinger, Naomi // Drugs;2008, Vol. 68 Issue 11, p1875 

    This article focuses on the drug febuxostat and its use in the treatment of hyperuricaemia and gout. The author explains febuxostat is the first new oral treatment for these diseases in 40 years. She believes that febuxostat may aid patients with sensitivity to other treatments and those with...

  • CHRONIC GOUT AND HYPERURICEMIA; TREATMENT WITH FEBUXOSTAT VERSUS ALLOPURINOL. Shah, Faaiz Ali; Khan, Haziqdad; Kifayatullah; Ismatullah; Durrani, Zulfiqar Ali; Khan, Zahir // Professional Medical Journal;2014, Vol. 21 Issue 1, p55 

    Objective: To assess the urate-lowering efficacy and safety of Febuxostat versus Allopurinol in subjects with hyperuricemia and gout. Study design: Randomized controlled trial. Place and duration of study: Department of Orthopaedic and Trauma Surgery Mardan Medical Complex Teaching Hospital...

  • New drugs: Febuxostat, lacosamide, and rufinamide. Hussar, Daniel A.; Bilbow, Caitlin // Journal of the American Pharmacists Association: JAPhA;May/Jun2009, Vol. 49 Issue 3, p460 

    The article offers information on the drugs febuxostat, lacosamide and rufinamide approved in the U.S. in 2009. Febuxostat, a xanthine oxidase inhibitor, is developed to treat chronic gout for patients over 40 years old. Lacosamide is an adjunctive treatment for epileptic patients whose ages...

  • Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. H. R. Schumacher; M. A. Becker; E. Lloyd; P. A. MacDonald; C. Lademacher // Rheumatology;Feb2009, Vol. 48 Issue 2, p188 

    Objectives. This 5-yr study assessed urate-lowering and clinical efficacy and safety of long-term febuxostat therapy in subjects with gout. The primary efficacy end-point was reduction to and maintenance of serum urate (sUA) levels <6.0 mg/dl. Methods. Subjects who completed a previous 28-day...

  • It Is Not What You Know That Gets You In Trouble, It Is What You Know That Is Not True. Davis, Neil M. // Hospital Pharmacy;Nov2009, Vol. 44 Issue 11, p935 

    The author emphasizes that the traditional way for administering oral colchicine to treat acute gout is no longer appropriate as of 2009. He cites a report stating that the U.S. Food and Drug Administration (FDA) has approved the Colcrys, the first oral colchicine product comprising of a...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics